Key genes involved in glioma cell differentiation, including ASCL1 and PTPRZ1-MET, have been shown to contribute to the development of a glioma stem cell phenotype, which is thought to be the source of resistance and relapse after initial treatment with checkpoint inhibitors (63, 64). The gene discussed is MET; the disease is central nervous system cancer.